Studies examining ovarian cancer cell lines and NSCLC patients samples identified that changes in CTR1 expression were linked to acquired cisplatin resistance and poor clinical outcome, and knockout of CTR1 in a murine model has been shown to eliminate the responsiveness of tumours to cisplatin (Holzer et al., 2004; Jandial et al., 2009; Kim et al., 2014; Larson et al., 2009). Here, SLC31A1 is linked to neoplasm.